Association of kidney function with cancer incidence and its influence on cancer risk of smoking: The Japan Multi‐Institutional Collaborative Cohort Study

Kurasawa, Shimon; Imaizumi, Tsutomu; Maruyama, Shoichi; Tanaka, Keitaro; Kubo, Yoko; Nagayoshi, Mako; Ikezaki, Hiroaki; Suzuki, Sadao; Koyama, Teruhide; Koriyama, Chihaya; Kadota, Aya; Katsuura‐Kamano, Sakurako; Kuriki, Kiyonori; Wakai, Kenji; Matsuo, Keitaro

doi:10.1002/ijc.34554

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Kitchlu et al (2022) found an increased risk of cancer in patients with CKD. Similarly, Kurasawa et al (2023) reported a U-shaped relationship between estimated glomerular filtration rate and cancer incidence. The FDA has previously warned about the potential risk of medullary thyroid cancer with glucagon-like peptide-1 receptor agonists.…”

Section: Discussionmentioning

confidence: 93%

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials

Du,

Cao,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: This study aimed to assess the tumor risk of finerenone in individuals with type 2 diabetes mellitus (T2DM) aggravated by chronic kidney disease (CKD).Methods: A thorough search in the OVID Medline, OVID EMBASE, and Cochrane Library databases from their creation through 2 November 2022 yielded randomized controlled trials (RCTs) reporting on the tumor risks of finerenone in patients with T2DM complicated with CKD. A pair of reviewers selected the relevant studies based on selection criteria, collected data, and assessed the methodological quality of eligible RCTs. The Peto odds ratio (OR) with a 95% confidence interval (CI) was calculated, and subgroup analysis of tumor nature, tumor origin system, tumor origin organ, and follow-up time was performed. Furthermore, Egger’s test was implemented to determine publication bias.Results: Four RCTs with 14,875 participants who had a low-to-moderate risk of bias were included. Compared with placebo treatment, finerenone did not increase the risk of overall neoplasms (Peto OR = 0.97; 95% CI, 0.83–1.14), malignant neoplasms (Peto OR = 1.03; 95% CI, 0.86–1.23), benign neoplasms (Peto OR = 0.94; 95% CI, 0.50–1.80), or in situ neoplasms (Peto OR = 0.14; 95% CI, 0.01–2.17). Subgroup analysis of the tumor origin system showed that finerenone was associated with an increased risk of malignant neoplasms of urinary tract compared with placebo treatment (Peto OR = 1.69; 95% CI, 1.07–2.67). The results were found to be robust in sensitivity analysis, and there was no indication of publication bias. Discussion: Finerenone is not associated with an increased risk of overall tumors, but it may be linked to an increased risk of malignant neoplasms in urinary tract. Additional well-planned cohort studies in larger research populations are needed to corroborate these findings.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022374101, Identifier CRD42022374101.

show abstract

Section: Discussionmentioning

confidence: 93%

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials

Du,

Cao,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The National Cancer Center's new 12 Articles on Cancer Prevention states that prevention and control of heavy drinking, smoking, and obesity are recommended [1]. Some cancers and malignancies have been determined or assumed to be caused by smoking or viruses, but some cancers are described in the paper as having no clear cause [2][3][4][5][6][7][8][9][10][11][12][13]. On the other hand, the authors initially focused on Kawasaki disease (KD) and found the epidemiological fact that "pollen may be the triggering factor for KD" in 2003, and since then, a total of four papers were reported until 2016 [14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

The Relationship Between Annual Airborne Pollen Levels and the Occurrence of Uterine Cancer, Cervical Cancer, Corpus Uteri Cancer, Prostate Cancer, Bladder Cancer, Stomach Cancer, Cancer of the Gallbladder and Bile Ducts, Malignant Lymphoma, and Cancer of Oral and Pharyngeal, and Laryngeal Cancer: A Retrospective Study Based on The National Registry Database of Cancer Incidence In Japan, 1975–2015

Awaya,

Kuroiwa

2023

Med Clin Sci

View full text Add to dashboard Cite

Background: In Japan, pollen counts increased between 1977 and 1987, including three peaks (1978- 1980, 1982, 1984-1986) coinciding with triphasic Kawasaki disease (KD) outbreaks. Epidemiological findings have been extensively accumulated that KD since 2003 and, from 2018 related specific intractable diseases such as systemic vasculitis, collagen diseases, inflammatory bowel diseases, idiopathic dilated cardiomyopathy and further from 2019 various cancers such as lung, breast, pancreatic, skin and kidney cancers may be correlated to pollen exposure (PE). Methods and results: To elucidate the effects of PE on occurrence of other cancers, we evaluated the annual occurrence of disorders in relation to pollen counts using data from a national database. Specifically, we evaluated the occurrence of uterine cancer, cervical cancer, corpus uteri cancer, prostate cancer, bladder cancer, stomach cancer, cancer of gallbladder and bile ducts (GBB), malignant lymphoma (ML), oral and pharyngeal cancer (o-phar. cancers), laryngeal cancer. During 1975–2015, the 1978-80 and 1984-1986 peaks of pollen scatter was the earliest big peaks with which simultaneous increase in occurrence of uterine, cervical, bladder, stomach, GBB, o-phar. cancers and laryngeal cancers. Furthermore, simultaneous outbreaks of each cancer coincided with subsequent ten peaks of pollen scatter till 2015. Our results showed statistically significant correlations for o-phar cancers, laryngeal, prostate and stomach cancers between the annual number of newly registered patients (nRPs) in the patient-registry year and annual pollen levels in the same patient-registry year. Significant correlations were also shown between the number of nRPs in the patient-registry year and annual pollen levels measured 1 year (GBB), 2 years (prostate), 3 years (corpus uteri, stomach, ML), 5 years (uterine), 6 years (uterine, corpus uteri, prostate, bladder, GBB), 7 years (o-phar, laryngeal) and, 9 and 16 years (cervical) before the patient-registry year. Conclusion: We assume that cumulative effects of PE in many cases within about 6 years and more before the diagnosis of cancers might possibly trigger onset of cancers when cumulative effects of PE as environmental stress overwhelmed immunoreactive threshold. The authors would like to discuss the triggering effect of PE (the action of PE to induce a carcinogenic state in humans) on humans as a compromised host, in the preliminary stages of cancer development, in which human papillomavirus is thought to be involved in the pathogenesis.

show abstract

Serum urea concentration and risk of 16 site-specific cancers, overall cancer, and cancer mortality in individuals with metabolic syndrome: a cohort study

Wu,

Wei,

et al. 2024

BMC Med

View full text Add to dashboard Cite

Association of kidney function with cancer incidence and its influence on cancer risk of smoking: The Japan Multi‐Institutional Collaborative Cohort Study

Cited by 4 publications

References 40 publications

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials

Serum urea concentration and risk of 16 site-specific cancers, overall cancer, and cancer mortality in individuals with metabolic syndrome: a cohort study

Contact Info

Product

Resources

About